FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Bunker	2. Issuer Name and Ticker or Trading Symbol Zentalis Pharmaceuticals, Inc. [ZNTL]									(Che	5. Relationship of Repor (Check all applicable) Director X Officer (give title			10% Owner					
(Last) C/O ZEN 530 SEVI	3. Date of Earliest Transaction (Month/Day/Year) 04/07/2020									,	Chief Operating Officer								
(Street) NEW YORK NY 10018					4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Ap Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person											erson			
(City)	ip) I - Non-Deriva	tive	Secu	rities	Acai	iired	Disn	nsed	of o	r Ben	eficial	ly Own	ed						
1. Title of Security (Instr. 3) 2. Transaction Date				2. Transaction	2A. Deer Execution		ed Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar				5. Amou Securitie Benefici Owned Followin	int of es ially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v	Amou	ınt	(A) or (D)	Price		Reporte Transac (Instr. 3	d tion(s)	(instr.	4)	(Instr. 4)
Common Stock 04/07								P		3.	50	A	\$	S 18	1,177	,177,982(1)		D	
Common Stock				11/23/2020				G	V	V 101,045		D	\$0		1,076,937		D		
Common Stock				11/23/2020				G	v	101	,045	A		\$0	101,045			Ι	See Footnote ⁽²⁾
Common Stock				11/23/2020				S ⁽³⁾		3,9	961	D	\$46.2791 ⁽⁴⁾		97,084			I	See Footnote ⁽²⁾
Common Stock				11/23/2020				S ⁽³⁾		4,0)64	D	\$46.7149(5)		93,020				See Footnote ⁽²⁾
Common Stock				11/23/2020				S ⁽³⁾		40	00	D	\$47.5452(6)		92,620			Ι	See Footnote ⁽²⁾
			Tab	ole II - Derivati (e.g., pu	ve S	ecuri calls, v	ties A warra	cqui	red, [option	Dispo ns, co	sed o	f, or l	Bene secur	ficially ities)	Owne	d			
Derivative Security (Instr. 3)	tive Conversion Date Executy or Exercise (Month/Day/Year) if any			3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			An Se Un De Se	Amount of Securities Underlying Derivative Security (Inst 3 and 4)		. Price of lerivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D or Indirect (I) (Instr.	Beneficial Ownership (Instr. 4)
				Code	v	/ (A)		Date Exercis		Expiratio Date		of	ares						

Explanation of Responses:

- 1. Includes 632,982 shares of common stock received on October 28, 2020 in a pro-rata distribution in-kind that was exempt from reporting under Rule 16a-9.
- 2. Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
- $3. \ The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.$
- 4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$45.47 to \$46.46. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$46.47 to \$47.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 6. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$47.51 to \$47.695. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kevin D. 11/25/2020 **Bunker**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.